The weekly injected drugs helped users lose weight with a much lower risk of gastrointestinal problems than popular GLP-1s, researchers say.
Recap by typeshit. Full story at U.S. News & World Report.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
Prosecutors say the fake pens came from China and hit over 150 pharmacies and businesses. One defendant was extradited from Italy, and each faces up to 71 years if convicted.
Presented at EASD, the analysis put Foundayo 17.2 mg ahead by 1.5% in weight loss and 0.3% in A1C at 52 weeks, though no head-to-head trial was run.
Loading…